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Background
For the development of biosimilar monoclonal antibodies
(mAb) or related substances containing the IgG Fc part it
is mandatory to fully compare immunological properties
between originator and biosimilar in a “comparability
exercise” [1]. The most complex Fc associated function to
mediate antibody dependent cellular cytotoxicity (ADCC)
needs to be characterized using the active substance of the
biosimilar and the comparator. From a regulatory point of
view potency assays should reflect the proposed mode of
action but in vitro ADCC assays are considered difficult to
validate due to the variability of the primary effector cells
[2,3]. The requirement to test for ADCC with high preci-
sion and accuracy is challenging. Design of cell lines to
replace primary cells for effector or target cells is a solu-
tion to provide tools for standardized and extensive biosi-
milar testing.
Materials and methods
Retroviral vectors were used to generate cell lines with
stable genetic modification. Vector particles were gener-
ated by transient transfection of 293T cells with plasmids
encoding gag, pol/env and an expression plasmid contain-
ing the packaging region and the sequences of promotor
and the transgenes, i.e. selection marker and gene of inter-
est. Multiple gene expression was achieved either by using
a bicistronic design enabling transcription from two pro-
motor sequences, or by using an internal ribosomal entry
site. Transduction of cells in log phase was followed by a
selection of transduced cells and clonal selection by limit-
ing dilution. Cell clones were expanded for primary and
secondary cell banks and further characterised with regard
to transgene expression and functional characteristics. We
developed a human transgenic NK-cell line (YTE756.
V#26, effector cell line) with stable expression of Fc
gamma-receptor IIIA (CD16, high affinity variant, valine
at position 159) and stable functional characteristics.
Target cell lines were generated similarly using different
expression plasmid constructs.
ADCC assays were developed by using design of experi-
ments (DoE) to determine experimental factors of impor-
tance for assay suitability. To show assay suitability
goodness of fit, the amplitude of sigmoid curve, slope and
parallelism was determined for each sample compared to
a standard. Hypo- and hyperpotent samples (50%, 100%,
150% and 200% potency) of Rituximab, Trastuzumab,
Adalimumab and Infliximab were analysed to determine
accuracy and linearity of each method. Optimisation of
each assay requires determining the relative importance of
factors including E:T ratio, incubation time, target cell
density and pre-assay schedules for target and effector
cells. Analysis of critical factor interaction was performed
using Minitab software. A list of established ADCC assays
is shown in Table 1.
CD16 expression was analyzed and quantified by flow
cytometry. Cells were stained using anti-CD16 PE-con-
jugated antibodies. PE-fluorescence was correlated to
number of PE-molecules per cell using BD Quantibrite
beads. Primary NK-cells were isolated using Dynal beads
(purity > 95%) from 3 healthy donors and used immedi-
ately after isolation.
Results
In order to prove genetic stability of the transgenic NK cell
line CD16 expression was analysed by flow cytometry for
up to 22 passages. More than 95% of cells were CD16
positive, viability of cells was >90%. CD16 expression level
was stable (19.000 - 28.000 CD16 molecules/cell).
Functional stability of the effector cell line was shown
for more than 30 passages. This was shown by a stable
EC50 value obtained for a reference antibody in the Tras-
tuzumab ADCC assay.
The effector cell line was compared with primary NK-
cells (purity > 95%) from 3 donors in a Trastuzumab
ADCC assay. The data show high donor variability,
mostly incomplete dose-response curves and a killing* Correspondence: Carsten.Lindemann@eufets.com
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activity with a low dynamic range (baseline to top ratio:
3). For primary NK-cells the amplitude of the dose-
response curve is dependent on both donor variability
and the type of target cell. Using the effector cell line
this is dependent on the target cell only. Assay variabil-
ity was strongly reduced and sample throughput could
strongly be increased by using the effector cell line in
comparison to primary NK-cells. Optimization of each
assay by DoE required determining the relative impor-
tance of various factors including effector to target cell
ratio, incubation time, target cell density and pre-assay
culture schedules for target and effector cells. Accuracy
of these ADCC assays could be shown in between a
range of 50% to 200% potency. Linearity was shown by
a high coefficient of determination (>0.97) and other
statistical methods. Inter-assay precision of all ADCC
assays was <20%.
ADCC assays for Infliximab and Adalimumab require
a membraneTNFalpha expressing target cell line (Table
1). In this fully designed ADCC test system both the
transgenic NK-effector cell line and the target cell line
were generated by genetic modification. In the presented
case, the test system consists of HT1080 target cells
modified to express membraneTNFalpha and the trans-
genic NK-cell line.
Accuracy and linearity of the Infliximab ADCC assay
was analysed by measuring items containing varying theo-
retical antibody concentrations to simulate hypo-potent
and hyper-potent samples. Linearity was shown by a high
coefficient of determination or by testing if the 2nd order
polynomial model is non-significant (0 is included in the
95% confidential interval of B2). For precision analysis the
relative potency of a sample was repeatedly analyzed on
4 days with 3 assays per day.
Table 1 ADCC assay systems
Antibody Target cell line Read-out Selection of cell line
Trastuzumab HER-2+ SK-OV-3 cells metabolic activity of residual target cells selected from various breast cancer cell lines
Rituximab CD20+ Granta-519 cells Calcein release by target cells selected from various hematopoietic tumor cell lines
Cetuximab EGFR+ SK-OV-3 cells metabolic activity of residual target cells selected from various breast cancer cell lines
Infliximab membraneTNFalpha+ 293T cells Calcein release by target cells generated by genetic modification
Adalimumab membraneTNFalpha+ HT1080 cells metabolic activity of residual target cells
Figure 1 Analysis of accuracy and linearity of the Infliximab ADCC assay. Data shown are sample dose response curves (left) determined
by 4PL analysis and mean rel. potency +/- SD (dot, n = 3) compared to the standard (right).
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Conclusions
Altogether these data show the feasibility of providing
suitable tools for validation and routine testing of var-
ious mAbs in ADCC potency assays scalable to the ana-
lytical needs of biosimilar testing.
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